AstraZeneca

NASDAQ: AZN · Real-Time Price · USD
72.11
-0.33 (-0.46%)
At close: May 05, 2025, 3:59 PM
72.10
-0.02%
After-hours: May 05, 2025, 07:48 PM EDT
-0.46%
Bid 72.01
Market Cap 447.15B
Revenue (ttm) 54.98B
Net Income (ttm) 7.77B
EPS (ttm) 2.48
PE Ratio (ttm) 29.08
Forward PE 13.28
Analyst Buy
Ask 72.2
Volume 2,184,614
Avg. Volume (20D) 6,250,035
Open 72.48
Previous Close 72.44
Day's Range 71.51 - 72.50
52-Week Range 61.24 - 87.68
Beta 0.18

About AZN

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardi...

Sector Healthcare
IPO Date May 12, 1993
Employees 94,300
Stock Exchange NASDAQ
Ticker Symbol AZN
Full Company Profile

Analyst Forecast

According to 5 analyst ratings, the average rating for AZN stock is "Buy." The 12-month stock price forecast is $95, which is an increase of 31.74% from the latest price.

Stock Forecasts
2 months ago
+2%
AstraZeneca shares are trading higher after the co... Unlock content with Pro Subscription
6 months ago
-7.22%
AstraZeneca shares are trading lower following a report suggesting that the company's insurance fraud involved senior executives in China.